Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04480307Phase 2Completed

Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis

Role: lead

NCT05049161Phase 2Terminated

A Long-term Extension of Study GNC-401

Role: lead

NCT01639300Phase 2Completed

Safety Study of GNbAC1 in Multiple Sclerosis Patients

Role: lead

NCT01804660Completed

Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Normal Population

Role: lead

NCT01804647Completed

Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease

Role: lead

NCT01699555Phase 1Completed

First-in-Human Study With GNbAC1 in Healthy Volunteers

Role: lead

NCT02452996Phase 1Completed

Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers

Role: lead

All 7 trials loaded